[go: up one dir, main page]

Suh et al., 2021 - Google Patents

Restoration of visual function in adult mice with an inherited retinal disease via adenine base editing

Suh et al., 2021

View PDF
Document ID
1207081037211408506
Author
Suh S
Choi E
Leinonen H
Foik A
Newby G
Yeh W
Dong Z
Kiser P
Lyon D
Liu D
Palczewski K
Publication year
Publication venue
Nature biomedical engineering

External Links

Snippet

Cytosine base editors and adenine base editors (ABEs) can correct point mutations predictably and independent of Cas9-induced double-stranded DNA breaks (which causes substantial indel formation) and homology-directed repair (which typically leads to low …
Continue reading at pmc.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00

Similar Documents

Publication Publication Date Title
Suh et al. Restoration of visual function in adult mice with an inherited retinal disease via adenine base editing
Choi et al. In vivo base editing rescues cone photoreceptors in a mouse model of early-onset inherited retinal degeneration
Meng et al. Therapy in rhodopsin-mediated autosomal dominant retinitis pigmentosa
Acland et al. Gene therapy restores vision in a canine model of childhood blindness
US20230330268A1 (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
Huang et al. Genome editing abrogates angiogenesis in vivo
Wu et al. AAV-mediated base-editing therapy ameliorates the disease phenotypes in a mouse model of retinitis pigmentosa
Gao et al. Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents
Zheng et al. Preventing autosomal-dominant hearing loss in Bth mice with CRISPR/CasRx-based RNA editing
Yu et al. Nrl knockdown by AAV-delivered CRISPR/Cas9 prevents retinal degeneration in mice
Xue et al. Gene editing in a Myo6 semi-dominant mouse model rescues auditory function
Doroudchi et al. Virally delivered channelrhodopsin-2 safely and effectively restores visual function in multiple mouse models of blindness
Haberman et al. Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion
N Sahni et al. Therapeutic challenges to retinitis pigmentosa: from neuroprotection to gene therapy
Vagni et al. Gene editing preserves visual functions in a mouse model of retinal degeneration
Stemerdink et al. Genetics, pathogenesis and therapeutic developments for Usher syndrome type 2
US11858969B2 (en) Engineered light-sensitive proteins
Fjord-Larsen et al. Increased encapsulated cell biodelivery of nerve growth factor in the brain by transposon-mediated gene transfer
Borras Advances in glaucoma treatment and management: gene therapy
Qu et al. Treating Bietti crystalline dystrophy in a high-fat diet-exacerbated murine model using gene therapy
Saidia et al. Current advances in gene therapies of genetic auditory neuropathy spectrum disorder
Lan et al. Recent development of AAV-based gene therapies for inner ear disorders
Cui et al. A base editor for the long-term restoration of auditory function in mice with recessive profound deafness
Ross et al. Outer retinal transduction by AAV2-7m8 following intravitreal injection in a sheep model of CNGA3 achromatopsia
Fu et al. In vivo prime editing rescues photoreceptor degeneration in nonsense mutant retinitis pigmentosa